Nyheter/rapporter

Senaste pressmeddelanden och rapporter för bevakat bolag.

Datum Källa Rubrik Typ Alternativ
2023-05-25 Vivesto Kommuniké från årsstämma i Vivesto AB Pressreleaser Ladda ner | Visa Stäng
2023-05-25 Vivesto Report from Annual General Meeting in Vivesto AB Pressreleaser Ladda ner | Visa Stäng
2023-05-25 Vivesto Interim report for the period January 2023 – March 2023 Rapporter Ladda ner | Visa Stäng
2023-05-25 Vivesto Delårsrapport för perioden januari – mars 2023 Rapporter Ladda ner | Visa Stäng
2023-04-25 Vivesto Notice of Annual General Meeting in Vivesto AB Pressreleaser Ladda ner | Visa Stäng
2023-04-25 Vivesto Kallelse till årsstämma i Vivesto AB Pressreleaser Ladda ner | Visa Stäng
2023-04-25 Vivesto Vivesto publishes Annual Report for 2022 Rapporter Ladda ner | Visa Stäng
2023-04-25 Vivesto Vivesto publicerar årsredovisning för 2022 Rapporter Ladda ner | Visa Stäng
2023-03-24 Vivesto Vivesto och Elevar avser överlåta Elevars rättigheter och skyldigheter för Apealea till tredje part Pressreleaser Ladda ner | Visa Stäng
2023-03-24 Vivesto Vivesto and Elevar seek to transfer Elevar’s Apealea rights and obligations to a third party Pressreleaser Ladda ner | Visa Stäng
Pressreleaser | 24 Mar 2023 | Vivesto

Vivesto and Elevar seek to transfer Elevar’s Apealea rights and obligations to a third party

Vivesto AB, an oncology-focused R&D company, has been informed that Elevar Therapeutics Inc., which holds the rights to commercialize Vivesto’s anticancer product Apealea, intends to transfer its rights and obligations to a third party. A transfer of rights and obligations would require Vivesto’s consent, and no such consent has been given yet.

A transfer may be in Vivesto’s interest in terms of Apealea’s commercialization and development progress. Considering the current uncertainty regarding the launch activities of Apealea, Vivesto will write down balance sheet items preliminary amounting in total to MSEK 190. The impairment charge and write down have no cash flow impact, nor any other material impact on the company’s financial position.

A new partner could reignite the Apealea project,” said Erik Kinnman, CEO of Vivesto. “We will together with Elevar vigorously explore any opportunities emerging in this new situation, and in parallel seek a partner for China, which we see as a considerable and prioritized market opportunity.

In 2020, Vivesto and Elevar entered into a global strategic partnership for the commercialization of Apealea, granting Elevar an exclusive right to commercialize Apealea. Under the arrangement Elevar has the right to sub-license Apealea to other strategic partners, and such sub-licenses have been granted to Inceptua SA in Europe, Taiba Middle East FZ LLC in certain countries throughout the MENA region, and to Tanner Pharma Group Inc. in South America.

Elevar has informed Vivesto that the company is discontinuing its efforts to develop and commercialize Apealea and instead seeks to transfer its rights and obligations Vivesto’s understanding is that launch activities and sales in Europe are developing slower than expected, partially dependent upon Elevar only being able to provide Inceptua with limited Apealea supply.

Vivesto’s view is that a transfer may be in Vivesto’s interest. Based on this, Vivesto has informed Elevar that Vivesto is open to evaluate a request by Elevar to transfer rights and obligations and Vivesto is ready to negotiate in good faith the terms for such transfer.

In light of the increased uncertainty relating to the commercialization of Apealea, Vivesto has made an impairment test of the book values of the project, which as of December 31, 2022 totalled MSEK 229, and decided to write down some of the capitalized development costs. The amount of impairment is preliminary calculated to MSEK 180, which will be recorded as an expense. In addition to this the inventory and other equipment will be written down with MSEK 10. The impairment charge and write down will be included in the annual report of 2022, which will be released in April, 2023. The impairment charge and write down have no cash flow impact, nor any other material impact on the company’s financial position.

For further information:

Erik Kinnman, Chief Executive Officer

Phone: +46 18-50 54 40

E-mail: IR@vivesto.com

About Vivesto AB
Vivesto is a research and development company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company has a growing portfolio of clinical-stage projects targeting advanced cancer. Apealea® (paclitaxel micellar) is made available to patients with ovarian cancer through a partnership with Elevar Therapeutics, Inc. Other development programs include Cantrixil, a clinical program in long-developed ovarian cancer, and Docetaxel micellar being developed for metastatic prostate cancer. Vivesto’s proprietary and patented technology platform is developed to improve the water solubility, efficacy and safety of pharmaceuticals. The company’s shares are traded on Nasdaq Stockholm (ticker: VIVE). Visit www.vivesto.com for more information about Vivesto.

This information is information that Vivesto AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, on [•] March 2023 at xx:xx CET.

2023-03-20 Vivesto Vivesto inleder klinisk utveckling av Paccal Vet inom veterinäronkologi Pressreleaser Ladda ner | Visa Stäng
2023-03-20 Vivesto Vivesto initiates clinical development of Paccal Vet in veterinary oncology Pressreleaser Ladda ner | Visa Stäng
2023-02-27 Penser Access Penser Access: Vi ser fram emot ökad tydlighet - Vivesto Pressreleaser Visa Stäng
2023-02-23 Penser Access Penser Access: Intervju med Vivesto - Erik Penser Bank - 23 februari 2023 Pressreleaser Visa Stäng
2023-02-23 Vivesto Bokslutskommuniké för räkenskapsåret 1 januari – 31 december 2022 Rapporter Ladda ner | Visa Stäng
2023-02-23 Vivesto Year-end report for the financial year January 1 – December 31, 2022 Rapporter Ladda ner | Visa Stäng
2023-02-02 Penser Access Penser Access: Korrigerat utskick: Intervju med Vivesto - Erik Penser Bank - 2 februari 2023 Analyser Visa Stäng
2023-02-02 Penser Access Penser Access: Intervju med Vivesto - Erik Penser Bank - 2 februari 2023 Analyser Visa Stäng
2023-01-11 Vivesto Vivesto meddelar Inceptuas beslut att återkalla ansökan om marknadsgodkännande för Apealea® i Schweiz Analyser Ladda ner | Visa Stäng
2023-01-11 Vivesto Vivesto announces Inceptua decision to withdraw market authorization application for Apealea® in Switzerland Analyser Ladda ner | Visa Stäng
2022-12-28 Vivesto Vivesto meddelar att Erik Kinnman tillträder sin VD befattning i januari Analyser Ladda ner | Visa Stäng
2022-12-28 Vivesto Vivesto announces Erik Kinnman to take up CEO position in January Analyser Ladda ner | Visa Stäng
2022-11-30 Vivesto Vivesto announces that Christer Nordstedt will remain as acting CEO during a transition period Analyser Ladda ner | Visa Stäng
2022-11-30 Vivesto Vivesto meddelar att Christer Nordstedt kvarstår som tillförordnad VD under en övergångsperiod Analyser Ladda ner | Visa Stäng
2022-11-21 Penser Access Penser Access: Ett uträtat frågetecken - Vivesto Analyser Visa Stäng
2022-11-21 Vivesto Vivesto utser Erik Kinnman till verkställande direktör Analyser Ladda ner | Visa Stäng
2022-11-21 Vivesto Vivesto appoints Erik Kinnman as CEO Analyser Ladda ner | Visa Stäng
2022-11-21 Vivesto Valberedning utsedd inför Vivestos årsstämma 2023 Analyser Ladda ner | Visa Stäng
2022-11-21 Vivesto Nomination Committee appointed for the 2023 Annual General Meeting in Vivesto Analyser Ladda ner | Visa Stäng
2022-11-17 Vivesto Interim report for the period January 1, 2022 – September 30, 2022 Analyser Ladda ner | Visa Stäng
2022-11-17 Vivesto Delårsrapport för perioden 1 januari – 30 september 2022 Analyser Ladda ner | Visa Stäng
2022-11-11 Vivesto Invitation to presentation of Vivesto’s Q3 report 2022 on November 17 Analyser Ladda ner | Visa Stäng
2022-11-11 Vivesto Inbjudan till presentation av Vivestos Q3-rapport den 17 nov Analyser Ladda ner | Visa Stäng
2022-11-03 Vivesto Christer Nordstedt avgår som tillförordnad VD för Vivesto Analyser Ladda ner | Visa Stäng
2022-11-03 Vivesto Christer Nordstedt resigns as acting CEO of Vivesto Analyser Ladda ner | Visa Stäng
2022-09-14 Penser Access Penser Access: Frågetecken behöver rätas ut - Vivesto Analyser Visa Stäng
2022-08-25 Vivesto Interim report for the period January 1, 2022 – June 30, 2022 Analyser Ladda ner | Visa Stäng
2022-08-25 Vivesto Delårsrapport för perioden 1 januari – 30 juni 2022 Analyser Ladda ner | Visa Stäng
2022-08-18 Vivesto Inbjudan till presentation av Vivestos Q2-rapport den 25 augusti Analyser Ladda ner | Visa Stäng
2022-08-18 Vivesto Invitation to presentation of Vivesto’s Q2 report 2022 on August 25 Analyser Ladda ner | Visa Stäng
2022-08-15 Vivesto Vivesto notes the launch of Apealea® in Germany by Inceptua Analyser Ladda ner | Visa Stäng
2022-08-15 Vivesto Vivesto rapporterar att Apealea® lanserats i Tyskland av Inceptua Analyser Ladda ner | Visa Stäng
2022-07-27 Finansinspektionen Finansinspektionen: Flaggningsmeddelande i Vivesto AB Pressreleaser Visa Stäng
2022-07-21 Vivesto Vivesto utser Christer Nordstedt till tillförordnad VD Analyser Ladda ner | Visa Stäng
2022-07-21 Vivesto Vivesto appoints Christer Nordstedt as acting CEO Analyser Ladda ner | Visa Stäng
2022-07-05 Vivesto Vivesto har beslutat att avveckla sin verksamhet i Ryssland Analyser Ladda ner | Visa Stäng
2022-07-05 Vivesto Vivesto winds down its activities in Russia Analyser Ladda ner | Visa Stäng
2022-07-04 Finansinspektionen Finansinspektionen: Flaggningsmeddelande i Vivesto AB Pressreleaser Visa Stäng
2022-07-01 Finansinspektionen Finansinspektionen: Flaggningsmeddelande i Vivesto AB Pressreleaser Visa Stäng
2022-06-30 Vivesto Vivesto appoints Robert Maiorana as acting CFO Analyser Ladda ner | Visa Stäng
2022-06-30 Vivesto Vivesto utser Robert Maiorana till tillförordnad CFO Analyser Ladda ner | Visa Stäng
2022-06-30 Finansinspektionen Finansinspektionen: Flaggningsmeddelande i Vivesto AB Pressreleaser Visa Stäng
2022-06-13 Vivesto Vivesto och verkställande direktör Francois Martelet har överenskommit om att avsluta anställningsförhållandet Analyser Ladda ner | Visa Stäng
2022-06-13 Vivesto Vivesto and CEO Francois Martelet have agreed on ending the employment relationship Analyser Ladda ner | Visa Stäng

Kommande händelser

24 Aug 2023 | Kvartalsrapport 2023-Q2
16 Nov 2023 | Kvartalsrapport 2023-Q3
22 Feb 2024 | Bokslutskommuniké 2023